Is Sensorion S.A. (ALSEN.PA) a Buy, Sell, or Hold?
PAR : ALSEN.PA
Sensorion S.A.
$0.2715 EUR
$0.0 (1.5%)
- Volume
- 671.96K
- Average Volume
- 1.65M
- Market Capitalization
- $83.08M
- P/E Ratio
- -2.77
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.81
- Year Low
- $0.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.59
Company Overview
PAR
Frédéric Chéreau
Biotechnology
Healthcare
ALSEN.PA
63
FR
EUR
Liquidity Metrics
0.03
4.59
4.59
1.73
0.00
Sales & Valuation
-$
35.70
1.84
-3.01
-0.09
Profitability
-$0.0979
-$29.43M
-1264.68%
-1466.87%
-58.01%
-50.84%
P/E Metrics
-2.77
0.56
0.56
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
-0.66
4/9
$42.92M
$57.89M
$13.41M
-$64.97M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Amit D. Munshi | Chairman & Interim CEO |
| Bernd Schmidt | Chief Technical Officer |
| Frederic Chereau | Chief Executive Officer |
| Laurent Desire | Head of Preclinical Development |
| Christine Le Bec | Head of CMC Gene Therapy |
| Laurene Danon | Chief Financial Officer |
| Rachel Cooper | Head of Audiology |
| Stephanie Filipe | Head of Business Operations & Portfolio Management |
Poll Results
No votes yet today — be the first to share your view!
About Sensorion S.A. (PAR:ALSEN.PA) Stock
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic ... analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
Frequently Asked Questions
-
What is the current Sensorion S.A. (ALSEN.PA) stock price?
-
Sensorion S.A.(PAR:ALSEN.PA) stock price is $0.2715 in the last trading session. During the trading session, ALSEN.PA stock reached the peak price of $0.808 while $0.222 was the lowest point it dropped to. The percentage change in ALSEN.PA stock occurred in the recent session was 1.5% while the dollar amount for the price change in ALSEN.PA stock was $0.0.
-
ALSEN.PA's industry and sector of operation?
-
The PAR listed ALSEN.PA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALSEN.PA?
-
Amit D. Munshi | Chairman & Interim CEO
Bernd Schmidt | Chief Technical Officer
Frederic Chereau | Chief Executive Officer
Laurent Desire | Head of Preclinical Development
Christine Le Bec | Head of CMC Gene Therapy -
How many employees does ALSEN.PA have?
-
Number of ALSEN.PA employees currently stands at 63. ALSEN.PA operates from 375, rue du Professeur Joseph Blayac, Montpellier, OC 34080, FR.
-
Link for ALSEN.PA official website?
-
Official Website of ALSEN.PA is: https://www.sensorion.com
-
How do I contact ALSEN.PA?
-
ALSEN.PA could be contacted at phone #33 4 67 20 77 30 and can also be accessed through its website. ALSEN.PA operates from 375, rue du Professeur Joseph Blayac, Montpellier, OC 34080, FR.
-
How many shares of ALSEN.PA are traded daily?
-
The average number of ALSEN.PA shares traded daily for last 3 months was 1.65M.
-
What is the market cap of ALSEN.PA currently?
-
The market value of ALSEN.PA currently stands at $83.08M with its latest stock price at $0.2715